Anson RM, Guo Z, de Cabo R, Iyun T, Rios M, Hagepanos A et al (2003) Intermittent fasting dissociates beneficial effects of calorie restriction
If exposed to high heat, contact the pharmacy before continuing to use the vial
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight
Unlike their older counterparts, these medications target the specific channels involved in abnormal pain signalling, without affecting healthy nerves
For type 2 diabetes, treatment continues as long as it remains safe and effective